This brand name is authorized in Hong Kong SAR China, Japan, Singapore.
The drug ROMIPLATE contains one active pharmaceutical ingredient (API):
1
|
UNII
GN5XU2DXKV - ROMIPLOSTIM
|
|
Romiplostim is an Fc-peptide fusion protein (peptibody) that signals and activates intracellular transcriptional pathways via the TPO receptor (also known as cMpl) to increase platelet production. |
|
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC Group | Classification | |
|---|---|---|
| B02BX04 | Romiplostim | B Blood and blood forming organs → B02 Antihemorrhagics → B02B Vitamin K and other hemostatics → B02BX Other systemic hemostatics |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| HK | Department of Health Drug Office | 63777 |
| JP | 医薬品医療機器総合機構 | 3999430D1024 |
| SG | Health Sciences Authority | 14688P |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.